The TLR7 agonist imiquimod has been approved for the treatment of genital warts caused by HPV. TLR3 and TLR7–9 agonists showed promising results for the treatment of viral infections ...

Its lead candidate, MBS8, consists of a small-molecule agonist of Toll-like receptor 7 (TLR7) in-licensed from the University of California San Diego, USA, and formulated by MonTa in collaboration ...

Imiquimod is an active substance that activates the innate receptors TLR7/8 and used to treat basal cell carcinomas. The researchers employed various preclinical mouse tumor models of melanoma and ...